Third Opinion Trial Synopsis
Doctors are testing a drug called mephalan to see how well it helps patients with multiple myeloma, a type of cancer. They want to know which dose of mephalan is the most effective and what side effects it has. Mephalan is a kind of medicine that can stop cancer cells from growing. In this trial, they're using a new way of dosing it based on each patient's blood levels of the drug, to find out how much they need and who will benefit most. By doing this, they hope to learn how to use mephalan better to help people with this kind of cancer.

Trial Summary
This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial uses a new method of dosing that is based on analysis of each individual's blood levels of melphalan after receiving a part of the dose, termed pharmacokinetic analysis. This may help to learn more about how to dose melphalan correctly and which patients are likely to benefit from a personalized dose.